Kestra Private Wealth Services LLC Sells 1,300 Shares of Sanofi (NASDAQ:SNY)

Kestra Private Wealth Services LLC decreased its stake in shares of Sanofi (NASDAQ:SNY) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,383 shares of the company’s stock after selling 1,300 shares during the period. Kestra Private Wealth Services LLC’s holdings in Sanofi were worth $1,113,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Rise Advisors LLC increased its position in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares in the last quarter. Salem Investment Counselors Inc. purchased a new stake in Sanofi during the 4th quarter valued at $27,000. Venturi Wealth Management LLC increased its holdings in shares of Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares in the last quarter. CNB Bank bought a new position in shares of Sanofi during the third quarter valued at $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in shares of Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $49.01 on Friday. The company has a 50-day moving average price of $47.89 and a 200-day moving average price of $48.27. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.93. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $123.98 billion, a P/E ratio of 24.63, a PEG ratio of 1.38 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Equities research analysts anticipate that Sanofi will post 4.12 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is currently 69.35%.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, Morgan Stanley started coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.